New Tekturna HCT approval in the US
This article was originally published in Scrip
Executive Summary
The US FDA has approved Novartis's combination antihypertensive Tekturna HCT (aliskiren and hydrochlorothiazide) for first-line use in patients who are likely to need more than one drug therapy to control their blood pressure.